Bowery Clinic Announces Evidence-Led Tesamorelin and Sermorelin Protocols Focused on Visceral Fat Reduction and Lean Mass Support

Audio By Carbonatix

NEW YORK, NY, January 14, 2026 (EZ Newswire) -- Bowery Clinic today announced expanded, physician-led protocols centered on two clinically studied peptides that act upstream of growth hormone: Tesamorelin (a growth hormone–releasing hormone analog) and Sermorelin (a GHRH 1–29 analog historically marketed as Geref). Bowery’s approach is built for patients seeking serious, medically supervised support for body composition, recovery, and metabolic health - grounded in the biology of the growth hormone (GH)-IGF-1 axis and informed by peer-reviewed data.

Unlike direct growth hormone administration, these therapies aim to stimulate endogenous, pulse GH signalling - an important distinction in how clinicians think about risk management, dosing strategy, and monitoring.

Why the GH–IGF-1 axis matters

Growth hormone is secreted in pulses from the pituitary and influences multiple downstream pathways, including IGF-1 production, substrate utilization (fat vs. glucose), tissue repair signaling, and body composition. In practice, “optimizing the axis” is not about chasing a number—it’s about aligning symptoms, labs, and measurable outcomes with safe physiology.

Bowery Clinic’s protocols emphasize:

• careful candidate selection
• baseline + follow-up lab monitoring (including IGF-1 and metabolic markers)
• conservative titration
• clear stop rules if risk outweighs benefit

Tesamorelin: the most clinically defined option in this category

Tesamorelin has the most established clinical profile among GH-axis peptides. It is FDA-approved (as EGRIFTA / EGRIFTA WR) for  reduction of excess abdominal fat (visceral adipose tissue) in HIV-infected adults with lipodystrophy, with important limitations (not indicated for weight loss; long-term cardiovascular safety has not been established).

Key clinical evidence

1. Visceral fat reduction and cardio-metabolic markers (HIV lipodystrophy)

A multi-center randomized trial published in The New England Journal of Medicine reported that daily Tesamorelin over 26 weeks reduced visceral by roughly 20% and improved lipid measures in HIV-infected patients with central fat accumulation.

2. Visceral fat reduction and metabolic/endocrine associations

Further work in Clinical Infectious Diseases examined how visceral adipose tissue reduction relates to endocrine and metabolic changes during Tesamorelin therapy in HIV-associated abdominal adiposity.

3. Liver fat and ectopic fat (HIV populations; investigational context)

A JAMA study evaluated effects of Tesamorelin on visceral and liver fat in HIV, supporting a broader scientific discussion of ectopic fat changes when endogenous pulsatile GH is increased.

A randomized, double-blind multicenter trial in Lancet HIV reported reductions in hepatic fat fraction in HIV-associated NAFLD, positioning tesamorelin as a studied (though not universally labeled) option in a complex metabolic subgroup.

How Bowery frames Tesamorelin for patients: Tesamorelin is the most defined GH-axis peptide because it has an FDA-approved indication, standardized manufacturing in its approved products, and a deep published literature in specific populations.

Sermorelin: a clinically studied GHRH analog with a different regulatory history

Sermorelin is a synthetic fragment of GHRH (1–29). It was previously FDA-approved as Geref (including pediatric and diagnostic indications), but the branded product was discontinued and moved to the Orange Book’s discontinued drug product list; FDA later determined it was not withdrawn for safety or effectiveness reasons.

This regulatory history matters: it’s one reason Sermorelin is commonly encountered today via individualized compounding rather than as a currently marketed FDA-approved brand.

Key clinical evidence

1. Restoring GH/IGF-1 signalling in older adults (GHRH 1–29 analog studies)

A randomized, placebo-controlled trial in The Journal of Clinical Endocrinology & Metabolism evaluated long-term administration of a GHRH (1–29) analog in older men and women, reporting endocrine-metabolic effects consistent with stimulating the somatotropic axis.

2. Cognitive endpoints studied with GHRH (1–29 NH2)

Work published in JAMA Neurology discusses randomized clinical trials of GHRH (1–29 NH2) administration in older adults (including those with mild cognitive impairment), examining cognitive outcomes alongside somatotropic effects.

Related PubMed records describe a 6-month GHRH intervention in healthy older adults with cognition as a primary focus.

How Bowery frames Sermorelin for patients: Sermorelin is best considered a clinician-managed, individualized GH-axis support option where dosing, timing, and monitoring determine whether benefits emerge—and whether risk remains acceptable. Its evidence base is real, but the modern supply pathway often involves compounding, which makes clinic standards and sourcing discipline more important, not less.

Bowery Clinic’s clinical standard: outcomes first, physiology always

Bowery Clinic’s GH-axis programs are structured like medical care-not a trend:

• Physician oversight and documented goals (body composition, recovery, metabolic markers)
• Baseline evaluation and exclusion criteria
• Ongoing monitoring (IGF-1, fasting glucose/HbA1c as appropriate, lipids; additional labs case-by-case)
• Clear criteria for pausing or discontinuing therapy if adverse signals appear
• Transparent discussions of what is known, what is uncertain, and what is off-label vs on-label

Tesamorelin’s FDA labeling highlights important limitations.

Safety and suitability: who should be cautious

GH-axis modulation is not appropriate for everyone. These therapies require medical evaluation and monitoring. Patients with certain histories (for example, some malignancies or conditions where GH/IGF-1 elevation could be concerning) may not be candidates. Tesamorelin’s prescribing information includes specific warnings and limitations that must be reviewed with a clinician.

Availability

Bowery Clinic’s Tesamorelin and Sermorelin programs are available through clinician evaluation with a defined monitoring plan and outcome tracking. Candidates are assessed individually, with care plans tailored to history, labs, and goals.

To learn more or request a clinical consult, patients can contact Bowery Clinic for an intake and physician review. Bowery Clinic provides peptide telehealth services to patients in New York, Florida, Michigan, Arizona, Washington, Illinois, New Jersey, California, Georgia, and Pennsylvania.

Bowery Clinic works exclusively with licensed 503A compounding pharmacies to ensure every medication meets the highest safety, purity, and sterility standards. We do not use or endorse research-grade peptides in any form, as they are not manufactured for human use and lack the regulatory protections required for safe medical treatment.

Disclaimer

Media Contact

Peter Arian

[email protected]

###

SOURCE: Bowery Clinic

https://app.eznewswire.com/news/bowery-clinic-tesamorelin-sermorelin-protocols-viral-fat-lean-mass